Class / Patent application number | Description | Number of patent applications / Date published |
514168000 | With a vitamin type active ingredient | 29 |
20080207570 | Topically applicable oil-in-water emulsions and dermatological applications thereof - Novel topically applicable oil-in-water emulsions, with a high proportion of oily phase in the inner phase, combine the occlusive and emollient properties of an ointment without having the drawbacks of a greasy feel, while at the same time promoting the therapeutic properties of a biologically active agent contained therein; such emulsions are especially useful for the treatment of dermatological diseases, conditions or afflictions, notably psoriasis. | 08-28-2008 |
20080221071 | Compositions for providing vitamin D year round and uses thereof - Methods for enhancing the ability of an individual, exposed to sunlight, to produce vitamin D via the skin. Pharmaceutical compositions comprising provitamin D and at least one of lumisterol and tachysterol and analogs and derivatives thereof are also disclosed. | 09-11-2008 |
20090163453 | Prevention and Treatment of Gastrointestinal and Bladder Disorders Associated with Chemotherapy or Radiation Therapy Using Active Vitamin D Compounds - The present invention relates to a method for preventing, treating, or ameliorating gastrointestinal and bladder disorders in a patient receiving a chemotherapy or radiation therapy comprising administering to the patient a therapeutically effective amount of active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound or a mimic thereof may be administered by high dose pulse administration so that high doses of the active vitamin D compound or a mimic thereof can be administered to an animal without inducing severe symptomatic hypercalcemia. | 06-25-2009 |
20090221538 | METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING PULSE DOSE CALCITRIOL - Prophylactic or therapeutic treatment to inhibit the development or progress of multiple sclerosis symptoms is provided by providing intermittently administered elevated doses of calcitriol, sufficiently infrequently to avoid hypercalcemia. Such methods may include maintaining at least about a normal blood level of vitamin D | 09-03-2009 |
20100087406 | INDUCTION OF INNATE IMMUNITY BY VITAMIN D3 AND ITS ANALOGS - Cationic antimicrobial peptides (AMPs) are an integral part of the innate immune system. Cathelicidin and defensin homologs from a variety of species exhibit broad-range bactericidal activity. The human cathelicidin analog, hCAP18, is encoded by the CAMP gene. Vitamin D | 04-08-2010 |
20100120728 | Method of Treating Vitamin D Insufficiency and Deficiency - The invention relates to methods and compositions for reducing toxicity associated with administration of vitamin D3, its 25-hydroxylated and 1-hydroxylated forms, and analogs thereof. | 05-13-2010 |
20100331286 | Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function - The field of the present invention relates to novel and improved therapies for treatment of complications associated with impaired renal function. More specifically, the present invention relates to evaluating the effects of a novel renal multivitamin on Vitamin D levels, EPO dose, inflammatory (e.g., C-reactive protein) and other biomarkers in an end stage renal disease (ESRD) population on hemodialysis (HD). | 12-30-2010 |
20110039810 | USE OF 25-HYDROXY-VITAMIN D3 TO AFFECT HUMAN MUSCLE PHYSIOLOGY - We disclose the use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 02-17-2011 |
20110039811 | TREATING HYPERGLYCEMIA WITH 25-HYDROXYVITAMIN D3 - We disclose treating hyperglycemia in a human with 25-hydroxyvitamin D3 (calcifediol). Blood glucose is reduced to a level which is closer to normal than baseline. Vitamin D3 (cholecalciferol) may optionally be used together with 25-hydroxy vitamin D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 02-17-2011 |
20110118218 | TREATING HYPERTENSION WITH 25-HYDROXYVITAMIN D3 - We disclose the use of optionally in combination with vitamin D3 (cholecalciferol), 25-hydroxyvitamin D3 (cal-cifediol), to treat hypertension. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 05-19-2011 |
20110124610 | METHOD FOR INCREASING BONE DENSITY AND/OR REDUCING ANY OSTEOCHONDRAL DEFECTS IN AN ANIMAL AND A COMPOSITION INCLUDING VITAMIN K - There is disclosed herein a method of increasing bone density, maintaining bone density and/or inhibiting loss of bone density and/or reducing osteochondral defects in an animal comprising administering to an animal an effective amount of a composition containing: vitamin K1, vitamin K2 or a mixture of vitamin K1 and vitamin K2, together with a physiologically acceptable carrier, incipient and/or diluent. Various compositions including vitamin K are also disclosed. | 05-26-2011 |
20110237558 | STABILIZED COMPOSITION FOR TREATING PSORIASIS - A storage stable ointment of the present invention comprises a vitamin D compound, a corticosteroid, and an N,N-di(C | 09-29-2011 |
20130137663 | METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS - Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxy vitamin D. | 05-30-2013 |
20130172299 | Combination Therapy for Treatment of Bone and Mineral Disorders for Patients with Impaired Renal Function - The field of the present invention relates to novel and improved therapies for treatment of complications associated with impaired renal function. More specifically, the present invention relates to evaluating the effects of a novel renal multivitamin on Vitamin D levels, EPO dose, inflammatory (e.g., C-reactive protein) and other biomarkers in an end stage renal disease (ESRD) population on hemodialysis (HD). | 07-04-2013 |
20130178451 | METHOD OF TREATING AND PREVENTING SECONDARY HYPERPARATHYROIDISM - The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D | 07-11-2013 |
20130210782 | TREATING HYPERGLYCEMIA WITH 25-HYDROXYVITAMIN D3 - We disclose treating hyperglycemia in a human with 25-hydroxyyitamin D3 (calcifediol). Blood glucose is reduced to a level which is closer to normal than baseline. Vitamin D3 (cholecalciferol) may optionally be used together with 25-hydroxy vitamin D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 08-15-2013 |
20130217655 | COMPOSITIONS FOR TREATING PSORIASIS OF THE SCALP - Compositions useful for the treatment of hyperproliferative dermal diseases of the scalp. Specifically, topical gel and liquid compositions that include calcipotriol and nicotinamide in a polyethylene glycol-based carrier, for topical application to the scalp. | 08-22-2013 |
20130316990 | USE OF VITAMIN D COMPOUNDS - Animal feed with 25-hydroxy vitamin D | 11-28-2013 |
20140066415 | Methods and Compounds for Vitamin D Therapy - Methods and compositions comprising 1,25-dihydroxyvitamin D | 03-06-2014 |
20140113886 | Stabilized 1, 25-Dihydroxyvitamin D2 and Method of Making Same - A stabilized 1,25-dihydroxyvitamin D | 04-24-2014 |
20140274977 | METHOD OF SAFELY AND EFFECTIVELY TREATING AND PREVENTING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE - A method of treating and preventing secondary hyperparathyroidism in CKD by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering 25-hydroxyvitamin D | 09-18-2014 |
20150025048 | METHODS FOR ENHANCING, IMPROVING, OR INCREASING FERTILITY OR REPRODUCTIVE FUNCTION - The present disclosure is directed to methods for enhancing, improving or increasing fertility or reproductive function. For example, the present disclosure is directed to a method for enhancing, improving, or increasing a female human's likelihood of becoming pregnant comprising: administering to the human a nutritional, dietary, or food fatty acid supplement comprising: at least 30% docosahexaenoic acid (DHA), by weight of the total fatty acids in the supplement in a form chosen from ethyl ester, free fatty acid, and triglyceride. | 01-22-2015 |
20150141386 | USE OF VITAMIN K TO DECREASE ALLOGRAFT FAILURE AND PATIENT MORTALITY AFTER ORGAN TRANSPLANTATION - Poor vitamin K status is provided as an independent risk factor for allograft failure and mortality in patients who received organ transplantation and who are under immunosuppressive medication. Various forms and recommended dosages of vitamin K, optionally combined with vitamin D and/or other immunosuppressive medication, are provided to optimize the treatment of such patients resulting in decreased allograft failure and improved patient survival. | 05-21-2015 |
20150359807 | Dietary Supplement Containing Vitamin A, D3 and Vitamin K2 and Uses Thereof - A composition comprising vitamin A, vitamin D and vitamin K | 12-17-2015 |
20160015723 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE EPIDERMAL DISEASES - The present invention provides compositions and methods for use in the treatment of hyperproliferative dermal diseases. Specifically, the present invention teaches pharmaceutical compositions for topical administration consisting essentially of a vitamin D metabolite, calcipotriol, and nicotinamide, which are particularly effective in treating and in the maintenance therapy of psoriasis and other related dermal disorders and diseases. | 01-21-2016 |
20160038513 | USE OF 25-HYDROXYVITAMIN D3 TO ENHANCE EXECUTIVE FUNCTIONS - This invention relates to the use of 25-hydroxyvitamin D3 (25-OH D3) to increase or maintain or alternatively, to lessen the decrease of the cognitive element known as executive functioning in healthy individuals. Optionally, 25-OH D3 may be administered in combination with Vitamin D or other ingredients. | 02-11-2016 |
20160067266 | STABILIZED COMPOSITION FOR TREATING PSORIASIS - A storage stable ointment of the present invention comprises a vitamin D compound, a corticosteroid, and an N,N-di(C | 03-10-2016 |
20160250160 | COMPOSITIONS FOR TREATING OR PREVENTING CARDIOVASCULAR DISEASE | 09-01-2016 |
20180021355 | Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease | 01-25-2018 |